Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R-COMP 14 vs R-COMP 21 in elderly aggressive B-cell non-Hodgkin lymphoma
2007-005613-19Phase 2Completed
- Sponsor
- San Salvatore Hospital of L'Aquila
- Start
- May 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of rituximab in non-Hodgkin lymphoma (NHL) (2 arms), sponsored by San Salvatore Hospital of L'Aquila. Primary endpoint: Safety and feasibility of R-COMP 14 and R-COMP 21. Started May 2008; status: completed.
02
Drugs
rituximab
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on 2007-005613-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-005613-19.